Dr. P. Paoletti
Member of the Board of Directors
Oncology Business Unit
Genmab A/S
Denmark
Biography
Dr. Paolo Paoletti, M.D. has been Independent Member of the Board of Directors of Genmab A/S since March 26, 2015. He was responsible for seven new medicines for cancer patients during his 10 years at GlaxoSmithKline and one new cancer medicine during his time at Eli Lilly. His last position in GSK was President of Oncology Business Unit. He is Acting CEO of GammaDelta Therapeutics and Chairman of the Board of PsiOxus Therapeutics Limited, as well as Member of the Board of FORMA Therapeutics, Inc. and NuCana BioMed Limited.
Research Interest
He has extensive experience in research, development and commercialization in the pharmaceutical industry and he successfully conducted submissions and approvals of new cancer drugs and new indications in the USA and in Europe.
